Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Deferred Taxes (2017 - 2025)

Haemonetics has reported Deferred Taxes over the past 11 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Deferred Taxes at -$2.1 million for Q4 2025, up 14.69% from a year ago — trailing twelve months through Dec 2025 was -$2.6 million (up 81.76% YoY), and the annual figure for FY2025 was -$5.2 million, up 52.72%.
  • Deferred Taxes for Q4 2025 was -$2.1 million at Haemonetics, down from -$725000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for HAE hit a ceiling of $3.4 million in Q1 2025 and a floor of -$15.9 million in Q2 2021.
  • Median Deferred Taxes over the past 5 years was -$2.2 million (2024), compared with a mean of -$2.2 million.
  • Peak annual rise in Deferred Taxes hit 593.2% in 2021, while the deepest fall reached 619.72% in 2021.
  • Haemonetics' Deferred Taxes stood at -$121000.0 in 2021, then surged by 2590.91% to $3.0 million in 2022, then tumbled by 207.66% to -$3.2 million in 2023, then rose by 25.52% to -$2.4 million in 2024, then rose by 14.69% to -$2.1 million in 2025.
  • The last three reported values for Deferred Taxes were -$2.1 million (Q4 2025), -$725000.0 (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.